✦ LIBER ✦

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

✍ Scribed by Jonathan J. Beitler; Richard V. Smith; Hilda Haynes; Carl E. Silver; Astrid Quish; Tamar Kotz; Maria Serrano; Allan Brook; Scott Wadler

Book ID: 110232130
Publisher: Springer US
Year: 1998
Tongue: English
Weight: 67 KB
Volume: 16
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1006102716920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical trial of parenteral hy

Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition

✍ Jonathan J. Beitler; Richard V. Smith; Randall P. Owen; Carl E. Silver; Madhu Ma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB 👁 2 views

## Abstract ## Background Almost all concurrent chemoradiation regimens for head and neck are platinum based; however, cisplatin is associated with severe renal, oto‐, and neurotoxicity. Hydroxyurea (HU) has been associated with fewer irreversible toxicities. We obtained HU in parenteral form to b

A phase I study of prolonged infusion 5-

A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck

✍ Burkhard Weppelmann; Ricarard H. Wheeler; Glenn E. Peters; Suzanne Stephens; Sha 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 439 KB

Neurotoxicity in a phase I trial of cont

Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer

✍ Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 569 KB

## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which

High-dose intra-arterial cisplatin and c

High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: Report of a phase II study

✍ William F. Regine; Joseph Valentino; William John; Gayle Storey; David Sloan; Da 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 3 views

Phase I trial of concurrent chemoradioth

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

✍ Katori, H; Tsukuda, M; Mochimatu, I; Ishitoya, J; Kawai, S; Mikami, Y; Matsuda, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

A Phase I/II trial of concurrent docetax

A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck

✍ Roy B. Tishler; Charles M. Norris Jr.; A. Dimitrios Colevas; Carolyn C. Lamb; Da 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract ## BACKGROUND The authors conducted a Phase I/II study in patients with a poor prognosis who had locally advanced squamous cell carcinoma of the head and neck (SCCHN) and who were treated initially with induction chemotherapy. Patients were treated with weekly docetaxel and concurrent